Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Co-Occurring Mutation Clusters Predict Drug Sensitivity in Acute Myeloid Leukemia

Guangrong Qin, PhD, Shmulevich Ilya, PhD, Taek-Kyun Kim, PhD, Bahar Tercan, PhD, Timothy J Martins, PhD, Jin Dai, PhD, Sylvia Chien, Andrew Carson, PhD, Bradley Patay, MD, Elihu H. Estey, MD, Lawrence A. Loeb, MD PhD, Raymond J. Monnat, MD PhD, Pamela S. Becker, MDPhD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-142727

Published: 2020

Journal Articles

High Throughput Drug Screening of Leukemia Stem Cells Reveals Resistance to Standard Therapies and Sensitivity to Other Agents in Acute Myeloid Leukemia

Frances Linzee Mabrey, MD, Sylvia S Chien, Timothy S Martins, PhD, James Annis, Taylor S Sekizaki, Jin Dai, PhD, Robert A. Beckman, MD, Lawrence A. Loeb, MD PhD, Andrew Carson, PhD, Bradley Patay, MD, Carl Anthony Blau, MD, Vivian G. Oehler, MD, Safiye S Celik, Su-In Lee, PhD, Raymond J. Monnat, MD PhD, Janis L. Abkowitz, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD, Pamela S Becker, MD PhD

Blood (2018) 132 (Supplement 1): 180.

https://doi.org/10.1182/blood-2018-180

Published: 2018

Journal Articles

Analysis of the Sub-Clonal Origins of Compound Mutations in Patients with Refractory Ph+ Malignancies Treated with Ponatinib

Justin R. Pritchard, PhD, Michael W. Schmitt, MD PhD, J. Graeme Hodgson, PhD, Stephanie Lustgarten, PhD, Shijie Tang, PhD, Lawrence A. Loeb, MD PhD, Jerald P. Radich, MD, Victor M. Rivera, PhD

Blood (2016) 128 (22): 1061.

https://doi.org/10.1182/blood.V128.22.1061.1061

Published: 2016

Journal Articles

Emergence of Sub-Clonal Drug Resistance Mutations during CML Therapy

Michael W. Schmitt, MD PhD, Justin R. Pritchard, PhD, Graeme Hodgson, PhD, Victor M. Rivera, PhD, Bella I. Aminov, Lan Beppu, Lawrence A. Loeb, MD PhD, Jerald P. Radich

Blood (2015) 126 (23): 478.

https://doi.org/10.1182/blood.V126.23.478.478

Published: 2015

Journal Articles

Targeted Ultra-Deep High Accuracy Sequencing of Pre-Treatment AML Reveals a Diversity of Mutational Phenotypes and Evidence of Preexisting Relapse-Associated Subclones

Marc J. Prindle, PhD, Lawrence A. Loeb, MD PhD, Elihu H. Estey, MD, Pamela S. Becker, MD PhD

Blood (2014) 124 (21): 2372.

https://doi.org/10.1182/blood.V124.21.2372.2372

Published: 2014

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Co-Occurring Mutation Clusters Predict Drug Sensitivity in Acute Myeloid Leukemia

High Throughput Drug Screening of Leukemia Stem Cells Reveals Resistance to Standard Therapies and Sensitivity to Other Agents in Acute Myeloid Leukemia

Analysis of the Sub-Clonal Origins of Compound Mutations in Patients with Refractory Ph+ Malignancies Treated with Ponatinib

Emergence of Sub-Clonal Drug Resistance Mutations during CML Therapy

Targeted Ultra-Deep High Accuracy Sequencing of Pre-Treatment AML Reveals a Diversity of Mutational Phenotypes and Evidence of Preexisting Relapse-Associated Subclones

Email alerts

ASH Publications

American Society of Hematology

Update search

Co-Occurring Mutation Clusters Predict Drug Sensitivity in Acute Myeloid Leukemia

High Throughput Drug Screening of Leukemia Stem Cells Reveals Resistance to Standard Therapies and Sensitivity to Other Agents in Acute Myeloid Leukemia

Analysis of the Sub-Clonal Origins of Compound Mutations in Patients with Refractory Ph+ Malignancies Treated with Ponatinib

Emergence of Sub-Clonal Drug Resistance Mutations during CML Therapy

Targeted Ultra-Deep High Accuracy Sequencing of Pre-Treatment AML Reveals a Diversity of Mutational Phenotypes and Evidence of Preexisting Relapse-Associated Subclones

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only